Case Report
Ocular metastases from HER2 positive breast carcinoma and the response to combination therapy with Paclitaxel and Trastuzumab: a case report
-
* Corresponding author: Konstantinos I Papageorgiou papagks@yahoo.com
1 Department of Ophthalmology, Broomfield Hospital, Mid Essex NHS Trust, Court Road, Chelmsford, Essex, CM1 7ET, UK
2 Capio Springfield Hospital, Lawn Lane, Springfield, Chelmsford, CM1 7GU, Essex, UK
Cases Journal 2009, 2:9143 doi:10.1186/1757-1626-2-9143
Published: 4 December 2009Abstract
Purpose
Breast cancer is the most common tumour to metastasize to the uveal tract. The mean survival period after diagnosis of metastasis to the eye, ranges from 10 to 32 months. However, recent advances in therapy including the use of monoclonal antibody therapy, will hopefully improve treatment outcomes and prolong survival rates.
Methods
We report a case of a 45 year old woman with a HER2 positive breast cancer, who developed two metastatic lesions in the left choroid, and the left optic nerve sheath. She underwent treatment with a combination of chemotherapy (Paclitaxel) and anti-HER2 monoclonal antibodies (Trastuzumab).
Results
Nine months after treatment, a B-scan showed resolution of the superior choroidal focus, as well as absence of blood flow within the optic nerve sheath. The inferonasal lesion was still present but the dimensions were reduced.
Conclusion
The patient underwent a combined treatment of chemotherapy and Trastuzumab to increase the response rate. Trastuzumab is a humanized monoclonal antibody, which binds to the extracellular segment of the HER2/neu receptor. Nine months following the therapy her vision was stable, whilst one focus of the tumour in the affected eye, had regressed. The favourable response highlights the significant impact of this new therapy, as an alternative to external beam radiotherapy in patients with ocular metastasis from HER2 (+) breast cancer.